Pylarify radiopharma
Ended Awarded Last action
- Contract number
- 36C25024F0285
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,239,365
Award facts
- Contract value 100% obligated
- $1,239,364.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $7,217 | |
| Funding Only Action | -$82,601 | |
| Funding Only Action | $306,741 | |
| Original award | $1,008,007 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., received a delivery order award valued at $1.24M from Veterans Integrated Service Network 10 for the supply of PYLARIFY (piflufolastat F-18) radiopharmaceuticals. This is a firm fixed-price contract with no set-aside designation, awarded on January 15, 2024, with completion targeted for December 31, 2024. The contract performance will be executed at the awardee's manufacturing and distribution facility in North Billerica, Massachusetts. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer, providing critical diagnostic capabilities for federal healthcare providers serving veterans.
This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract, which serves as the parent vehicle enabling the Department of Veterans Affairs and its constituent Veterans Integrated Service Networks to procure radiopharmaceutical products efficiently. Progenics Pharmaceuticals has an established federal contracting presence as a specialized supplier of diagnostic imaging agents, having received over 150 federal contract awards across multiple agencies including the VA, Defense Health Agency, and National Institutes of Health. The broader contracting relationship between Lantheus Holdings, Inc. and the VA includes a $290M Federal Supply Schedule contract extending through March 31, 2030, positioning the company as a primary supplier for radiopharmaceutical procurement across the federal healthcare system.
Quick answers
Who was awarded contract 36C25024F0285?
36C25024F0285 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on January 15, 2024.
How much is contract 36C25024F0285 worth?
The government has obligated $1,239,365 on 36C25024F0285.
Is contract 36C25024F0285 an order under another contract?
Yes. 36C25024F0285 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25024F0285 competed?
The extent of competition for 36C25024F0285 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award